Ketjussa on ollut vilkasta, mutta nyt toivottavasti vilkastuu lisää, sillä on ilmestynyt merkittävä julkaisu, joka kyseenalaistaa lasten rokotukset suhteessa rokotusten aiheuttamien kuolemien yleisyyteen. Pähkinänkuoressa: alkuperäisissä rokotekokeissa oli puutteita liittyen piikkiproteiinin mahdollisiin haittoihin, joita niissä ei käsitelty, ja sen vuoksi nyt havaitut kuolemanriskit nuorimmissa ikäluokissa puoltavat rokotusten keskeyttämistä jopa alle 35-vuotiailla, mutta ainakin lapsilla (12-16 v.), kunnes saadaan tarkempaa tietoa riskeistä heille.
Tämä ei tullut ihan puskista, sillä pari päivää sitten Yhdysvaltain THL:ä vastaava viranomainen FDA piti palaverin, jossa tuli ilmi jopa 1/1000 kuolemanriski rokotteesta. Samansuuntaisia lukuja kerrotaan saadun Britanniassa, mutten löytänyt vielä kunnon lähdettä tälle.
Tämä kyseinen julkaisu perustuu juurikin FDA:n VAERS-järjestelmän dataan ja siinä arvioitu kuolemanriski oli jopa lähemmäs 2/1000 eli 1/500. Eli yksi viidestäsadasta kuukahtaisi rokotteeseen. Riskiarviossa oli otettu huomioon vain viikon sisällä kuolleet, joten jos vaikutus voi tulla viiveellä, on todellinen riski tätäkin suurempi.
Tutkimus on julkaistu hyvää keskitasoa olevassa kansainvälisessä vertaisarvioidussa julkaisussa:
https://www.sciencedirect.com/science/a ... 002100161X
Lainausta:
Why are we vaccinating children against COVID-19?
The bulk of the official COVID-19-attributed deaths per capita occur in the elderly with high comorbidities, and the COVID-19 attributed deaths per capita are negligible in children. The bulk of the normalized post-inoculation deaths also occur in the elderly with high comorbidities, while the normalized post-inoculation deaths are small, but not negligible, in children. Clinical trials for these inoculations were very short-term (a few months), had samples not representative of the total population, and for adolescents/children, had poor predictive power because of their small size. Further, the clinical trials did not address changes in biomarkers that could serve as early warning indicators of elevated predisposition to serious diseases. Most importantly, the clinical trials did not address long-term effects that, if serious, would be borne by children/adolescents for potentially decades.
...
A paper published in NEJM in December 2020 [34] summarized the Phase 1 results. The focus was on local and systemic adverse events and efficacy metrics (antibody responses). The only metrics other than these reported were transiently decreased lymphocyte counts.
We view this level of reporting as poor safety science for the following reasons. Before the clinical trials had started, many published articles were reporting serious effects associated with the presence of the SARS-CoV-2 virus such as hyperinflammation, hypercoagulation, hypoxia, etc. SARS-CoV-2 includes the S1 Subunit (spike protein), and it was not known how much of the damage was associated with the spike protein component of SARS-CoV-2. A credible high-quality safety science experiment would have required state measurements of specific biomarkers associated with each of these abnormal general biomarkers before and after the inoculations, such as d-dimers for evidence of enhanced coagulation/clotting; CRP for evidence of enhanced inflammation; troponins for evidence of cardiac damage; occludin and claudin for evidence of enhanced barrier permeability; blood oxygen levels for evidence of enhanced hypoxia; amyloid-beta and phosphorylated tau for evidence of increased predisposition to Alzheimer’s disease; Serum HMGB1, CXCL13, Dickkopf-1 for evidence of an increased disposition to autoimmune disease, etc. A credible high-quality safety science experiment would have required flux measurements of products resulting from the mRNA interactions, from the LNP shell interactions, from dormant viruses that might have been stimulated by the mRNA-generated spike protein, etc., emitted through the sweat glands, faeces, saliva, exhalation, etc.
Most importantly, these types of measurements would have shown changes in the host that did not reach the symptom level of expression but raised the general level of host abnormality that could predispose the host to a higher probability of serious symptoms and diseases at some point in the future. Instead, in the absence of high-quality safety science reflected in these experiments, all that could be determined were short-term adverse effects and deaths. This focus on symptoms masked the true costs of the mRNA intervention, which would probably include much larger numbers of people whose health could have been degraded by the intervention as evidenced by increased abnormal values of these biomarkers. For example, the trials and VAERS reported clots that resulted in serious symptoms and deaths but gave no indication of the enhanced predisposition to forming serious clots in the future with a higher base of micro-clots formed because of the mRNA intervention. The latter is particularly relevant to children, who have a long future that could be seriously affected by having an increased predisposition to multiple clot-based (and other) serious diseases resulting from these inoculations.
...
The main objective of credible biodistribution studies (of inoculants for eventual human use) is to identify the spatio-temporal distribution of the actual inoculant in humans; i.e., how much of the final desired product (in this case, expressed protein antigen/spike protein) is produced in different human tissues and organs as a function of time. That’s not what was reported in the Pfizer Confidential study.
Rats were used for the in vivo studies; the relationship of their biodistribution to that of humans is unclear.
...
The many studies referenced above indicate collectively that the mRNA-based COVID-19 inoculations (the most prolific inoculations used in the USA for COVID-19 so far) consist of (at least) two major toxins: the instructions for the spike protein (mRNA) and the mRNA-encapsulating synthetic fat LNP. The vaccine is injected into the deltoid muscle, at which time it contributes to inflammation at the injection site due in part to the LNP and potentially to anaphylaxis from the LNP PEG-2000 component. Some of the injected material stays at the injection site, where it combines with cells through endocytosis to express spike protein on the cell surface, stimulating the adaptive immune system to eventually produce antibodies to the spike protein.
The remainder of the injected material enters the lymphatic system and the bloodstream, and is distributed to tissues and organs throughout the body..
...
These effects can occur throughout the body in the short term, as we are seeing with the VAERS results. They can occur in the mid- and long-term as well, due to the time required for destructive processes to have full effect and the administration of further inoculations.
...
...the main reasons why we believe the spike protein could be harmful to children even though they don’t seem to get sick from exposure to SARS-CoV-2 are 1) the bypassing of the innate immune system by inoculation, 2) the larger volume of spike protein that enters the bloodstream, and 3) the additional toxic effects of the encapsulating LNP layer.
...
Two issues arise from these results.
First, where is the data justifying inoculation for children, much less most people under forty? ... There appear to be no benefits for the children and young adults from the inoculations and only Costs! The second issue is why the deaths shown on Fig. 2 were not predicted by the clinical trials.
...
It is becoming clear that the central ingredient of the injection, the recipe for the spike protein, will produce a product that can have three effects. Two of the three occur with the production of antibodies to the spike protein. ... The third occurs when the injected material enters the bloodstream and circulates widely, which is enabled by the highly vascular injection site and the use of the PEG-2000 coating.
This allows spike protein to be manufactured/expressed in endothelial cells at any location in the body, both activating platelets to cause clotting and causing vascular damage. It is difficult to believe this effect is unknown to the manufacturer, and in any case, has been demonstrated in myriad locations in the body using VAERS data. There appears to be modest benefit from the inoculations to the elderly population most at risk, no benefit to the younger population not at risk, and much potential for harm from the inoculations to both populations. It is unclear why this mass inoculation for all groups is being done, being allowed, and being promoted.
Artikkelissa todetaan, että koronaan kuolee etupäässä vanhempia ihmisiä, ja lasten kohdalla riski on mitätön. Myös rokotehaitoissa eniten kuolleita on vanhoissa, mutta lasten kohdalla riski
ei ole enää mitätön. Eli rokote on nyt kerätyn datan perusteella lapsille vaarallisempi kuin itse tauti.
Rokotekokeissa oli kirjoittajien mukaan useita puutteita sekä rottakokeissa, että ihmistesteissä. Ihmiskokeissa ei otettu kokeita, joista olisi selvinnyt mm. veritulppien muodostuminen, aineen leviäminen elimistössä, autoimmuuniriski ym. Rokotetesteissä ikäryhmän 12-17 koko oli vain noin 100 lasta, kun vanhempia ihmisiä oli noin 14700 (ja saman verran vertailuryhmissä), joten lasten osalta myös ryhmän pieni koko on voinut haitata tuloksia.
Kirjoittajien mukaan koronakuolemat näyttävät liittyvän vahvasti kuolleiden henkilöiden huonoon vastustuskykyyn. He tuovat esiin, että tartuttajina joissain tutkimuksissa pahimmat ryhmät olivat vanhukset ja sylilapset, eivät kouluikäiset ja nuoret. Silti aivan pieniä lapsia ei ole juurikaan menehtynyt.
Koronataudin suurimmat ei-välittömät ongelmat liittyvät pitkäaikaisvaikutuksiin svt-tautien osalta. Artikkelista käy selväksi, että rokotteen piikkiproteiinin juuri näitä pitkäaikaisvaikutuksia olisi pitänyt tarkemmin selvittää. Samoin heidän mukaansa olisi pitänyt selvittää myös esimerkiksi sitä, mitä rokotteen ainesosat tekevät eri elimissä, esim. aivoissa, jonne ne hiirikokeiden mukaan pääsevät.
Kirjoittajat ehdottavatkin uusia arviointeja, joissa selvitettäisiin nyt avoinna olevia asioita.
Aika harvoin näkee tieteellisessä artikkelissa näin kovaa tekstiä, mitä tämän artikkelin johtopäätöksissä on. Toivottavasti artikkeli luetaan myös THL:ssä.